The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 14, 2025
Filed:
Sep. 25, 2020
Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;
Institut Régional Du Cancer DE Montpellier, Montpellier, FR;
Université DE Montpellier, Montpellier, FR;
Sorbonne Université, Paris, FR;
André Pelegrin, Montpellier, FR;
Bruno Robert, Montpellier, FR;
Pierre Martineau, Montpellier, FR;
Maëva Chauvin, Montpellier, FR;
Myriam Chentouf, Montpellier, FR;
Nathalie Di Clemente-Besse, Paris, FR;
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Paris, FR;
INSTITUT REGIONAL DU CANCER DE MONTPELLIER, Montpellier, FR;
UNIVERSITE DE MONTPELLIER, Montpellier, FR;
SORBONNE UNIVERSITE, Paris, FR;
Abstract
In ovarian carcinoma, Müllerian Inhibiting Substance (MIS) type II receptor (MISRII) and the MIS/MISRII signaling pathway are potential therapeutic targets. Conversely, the role of the three MIS type I receptors (MISRI; ALK2, ALK3 and ALK6) in this cancer needs to be clarified. Using four ovarian cancer cell lines and ovarian cancer cells isolated from patients' tumor ascites, the inventors found that ALK2 and ALK3 are the two main MISRIs involved in MIS signaling at low and high MIS concentrations, respectively. Moreover, high MIS concentrations were associated with apoptosis and decreased clonogenic survival, whereas low MIS concentrations improved cancer cell viability. Finally, the inventors showed that anti-MIS antibody B10 inhibited MIS pro-survival effect. These last results open the way to an innovative therapeutic approach to suppress MIS proliferative effect, instead of administering high doses of MIS to induce cancer cell apoptosis.